TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30760336

Group type: EXPERIMENTAL
Intervention: Adherence to UK dietary guidelines (DG)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (traditional UK diet)
Number of subjects: 161
Study: 28931976

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 34

Group type: COMPARATOR
Intervention: Classical physiotherapy program (home exercise, hot pack, TENS, ultrasound)
Number of subjects: 34
Study: 25982544

Group type: EXPERIMENTAL
Intervention: simvastatin (80 mg) once daily
Number of subjects: 142

Group type: COMPARATOR
Intervention: placebo once daily
Number of subjects: 142
Study: 23773343

Group type: EXPERIMENTAL
Intervention: 3-face scale preceded by a yes-no question
Number of subjects: 184

Group type: COMPARATOR
Intervention: Faces Pain Scale-Revised
Number of subjects: 184
Study: 21515905

Group type: EXPERIMENTAL
Intervention: Mental rehearsal of upper limb movements during 45-min supervised sessions three times a week and structured independent sessions twice a week
Number of subjects: 121

Group type: COMPARATOR
Intervention: Non-motor mental rehearsal (control group)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Normal care without additional training (control group)
Number of subjects: 121
Study: 19368503

Group type: EXPERIMENTAL
Intervention: Selenium supplements (200 microg of selenomethionine)
Number of subjects: 915
Study: 16886974

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) 20-30 mg/day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400-800 mg/day
Number of subjects: 105

Group type: COMPARATOR
Intervention: No-drug group (untreated patients)
Number of subjects: 105
Study: 14993550

Group type: EXPERIMENTAL
Intervention: Early inhaled nitric oxide (iNO) therapy
Number of subjects: 299

Group type: COMPARATOR
Intervention: Simulated initiation of iNO (control)
Number of subjects: 299
Study: 11317659

Group type: EXPERIMENTAL
Intervention: Intensive blood-glucose control with metformin (n = 342)
Number of subjects: 753

Group type: COMPARATOR
Intervention: Conventional therapy primarily with diet (n = 411)
Number of subjects: 753
Study: 9135180

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 234

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 234
Study: 8107555

Group type: EXPERIMENTAL
Intervention: Acetaminophen administered intragastrically in a single dose of 1.0 g.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (free from occupational exposure).
Number of subjects: 42
Study: 2904424

Group type: EXPERIMENTAL
Intervention: Synchronized hysteroscopic insemination (SHIFT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-SHIFT synchronized cycles
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hysteroscopic insemination procedure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Follicular stimulation protocol
Number of subjects: 40
Study: 4699272

Group type: EXPERIMENTAL
Intervention: Educational program for nurse practitioners
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (conventional office nurses)
Number of subjects: 14
Study: 31926063

Group type: EXPERIMENTAL
Intervention: BioBase mobile app and paired wearable device (BioBeam) used daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 29068800

Group type: EXPERIMENTAL
Intervention: R0 resection margin (>1 mm)
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: R1 resection margin (<1 mm)
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: R1 direct positive margins
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: R1 direct positive resection margin status
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Positive lymph node status
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: WHO performance status ≥1
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: R1 direct positive superior mesenteric/medial margin resection status
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: R1 direct tumor margins, poor tumor differentiation, positive lymph node status, WHO performance status ≥1, maximum tumor size, and R1 direct posterior resection margin
Number of subjects: 1151
Study: 28688704

Group type: EXPERIMENTAL
Intervention: Echocardiographic hypo-responders to CRT-D
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Clinical hypo-responders to CRT-D
Number of subjects: 534
Study: 25956233

Group type: EXPERIMENTAL
Intervention: Gait-assistance robot (GAR) assisted gait training (GAGT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Overground conventional gait training (OCGT)
Number of subjects: 26
Study: 23817682

Group type: EXPERIMENTAL
Intervention: Low-dose CT-guided biopsy (group B: 120 kv; 10 mA; thickness, 2.0 mm; pitch, 23 mm/rot)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional CT-guided biopsy (group A: 120 kv; 200 mA; thickness, 2.0 mm; pitch, 16 mm/rot)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-dose CT-guided biopsy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional CT-guided biopsy
Number of subjects: 90
Study: 22045831

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC; 50 mg/kg by 4 hours followed by 100 mg/kg/d for 48 hours diluted in 5% glucose) and deferoxamine (DFX; at a single dose of 1000 mg diluted in 5% glucose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus deferoxamine (DFX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19745592

Group type: EXPERIMENTAL
Intervention: Bendamustine (200 mg flat dose on days 1 + 2, repeated at day 28 or upon recovery of neutrophils)
Number of subjects: 22
Study: 17261096

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 144

Group type: COMPARATOR
Intervention: Minimal acupuncture
Number of subjects: 144
Study: 15371808

Group type: EXPERIMENTAL
Intervention: LMX (lidocaine 4%) applied 45 minutes before meatotomy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: LMX (lidocaine 4%) applied 30 minutes before meatotomy
Number of subjects: 52

Group type: COMPARATOR
Intervention: EMLA (lidocaine 2.5% and prilocaine 2.5%) applied 45 minutes before meatotomy
Number of subjects: 52

Group type: COMPARATOR
Intervention: EMLA (lidocaine 2.5% and prilocaine 2.5%) applied 30 minutes before meatotomy
Number of subjects: 52
Study: 11428852

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 3525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3525
Study: 9742282

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8113060

Group type: EXPERIMENTAL
Intervention: Process evaluation information collection in a school-based multicenter trial
Number of subjects: 96
Study: 3416618

Group type: EXPERIMENTAL
Intervention: Orally administered melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bright light exposure (to suppress serum melatonin levels)
Number of subjects: 0
Study: 30717691

Group type: EXPERIMENTAL
Intervention: Lower range group (LRG) 0.8‐1.4 mmol/L or 2.5‐4.3 mg/dL
Number of subjects: 104

Group type: COMPARATOR
Intervention: Higher range group (HRG) 1.8‐2.4 mmol/L or 5.6‐7.4 mg/dL
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 29288172

Group type: EXPERIMENTAL
Intervention: eSano BackCare‐D
Number of subjects: 210

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 210
Study: 26427912

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 82
Study: 24364175

Group type: EXPERIMENTAL
Intervention: MGCSH mixed with PRP (test group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Collagen resorbable plug (control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 14
Study: 21975926

Group type: EXPERIMENTAL
Intervention: Platycodi radix extract standardized to 414 mg of platycodin D
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 17921065

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 338

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 338
Study: 17290690

Group type: EXPERIMENTAL
Intervention: 3D vision
Number of subjects: 224

Group type: COMPARATOR
Intervention: 2D vision
Number of subjects: 224
Study: 12661753

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg once daily for 16 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 10738954

Group type: EXPERIMENTAL
Intervention: Noncontingent reinforcer delivery (NCR) with high-preference stimulus
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Noncontingent reinforcer delivery (NCR) with low-preference stimulus
Number of subjects: 1
Study: 8959469

Group type: EXPERIMENTAL
Intervention: Ceruletide (2.5 micrograms)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 32
Study: 1524743

Group type: EXPERIMENTAL
Intervention: Plax prebrushing mouthrinse
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control rinse
Number of subjects: 149
Study: 3928508

Group type: EXPERIMENTAL
Intervention: 100 mg Voltaren (diclofenac-sodium) before surgery and then 50 mg 3 times a day for 5 days
Number of subjects: 190

Group type: COMPARATOR
Intervention: Fixed combination tablets (acetylsalicylic acid 500 mg, caffeine 50 mg, aprobarbital 20 mg, codeine phosphate 10 mg) in the highest recommended dose, 2 tablets when needed at most 3 times a day
Number of subjects: 190
Study: 31279647

Group type: EXPERIMENTAL
Intervention: Angioplasty plus routine stenting
Number of subjects: 88

Group type: COMPARATOR
Intervention: Angioplasty only
Number of subjects: 88
Study: 29141477

Group type: EXPERIMENTAL
Intervention: Referrals containing information on low SES
Number of subjects: 107

Group type: COMPARATOR
Intervention: Referrals without information on low SES
Number of subjects: 107
Study: 26639943

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg once daily with normal-carbohydrate diet (NCD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg once daily with low-carbohydrate diet (LCD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo with normal-carbohydrate diet (NCD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo with low-carbohydrate diet (LCD)
Number of subjects: 18
Study: 24581393

Group type: COMPARATOR
Intervention: Induction chemotherapy followed by external beam radiotherapy (EBRT) with concomitant cisplatin (Arm A)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by EBRT with concomitant cisplatin plus brachytherapy boost (Arm B)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Induction chemotherapy followed by EBRT with concomitant cisplatin (Arm A)
Number of subjects: 274
Study: 22933542

Group type: EXPERIMENTAL
Intervention: Vitamin D(3), 50,000 IU monthly (n = 102)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo (n = 101)
Number of subjects: 203
Study: 20051890

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 18085909

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 0
Study: 15013324

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cyclosporine microemulsion (CsA)
Number of subjects: 35
Study: 11576201

Group type: EXPERIMENTAL
Intervention: Valproic acid (300 to 1200 mg per day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Valproic acid (serum levels >50 microg/mL)
Number of subjects: 52
Study: 9819872

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate 5 mg-patches
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 40
Study: 7664505

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2712434

Group type: EXPERIMENTAL
Intervention: NO2 exposure (2 ppm)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: NO2 exposure (3 ppm)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: NO2 exposure (1 ppm)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 152
Study: 320670

Group type: EXPERIMENTAL
Intervention: Topical clotrimazole
Number of subjects: 66

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 66
Study: 31801502

Group type: EXPERIMENTAL
Intervention: EndExam group (exam at the end of the BLS training)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: 3mExam group (exam 3 months after the BLS training)
Number of subjects: 464

Group type: COMPARATOR
Intervention: NoExam group (no exam)
Number of subjects: 464
Study: 28244635

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once daily for 26 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study: 26135706

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone 1000 mg once a day for 3 days
Number of subjects: 199

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone 1000 mg once a day for 3 days
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone
Number of subjects: 199

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 199
Study: 23880625

Group type: EXPERIMENTAL
Intervention: B lactis + GOS/FOS (10 colony-forming units/g + 0.4 g/100 mL)
Number of subjects: 528

Group type: COMPARATOR
Intervention: B lactis (10⁷ colony-forming units/g)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: B lactis + GOS/FOS
Number of subjects: 528

Group type: COMPARATOR
Intervention: B lactis
Number of subjects: 528
Study: 21842019

Group type: EXPERIMENTAL
Intervention: Toothbrush age at 4 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Toothbrush age at 8 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Toothbrush age at 12 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Toothbrush age at 16 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lingual/palatal surfaces
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Toothbrush wear index
Number of subjects: 110

Group type: COMPARATOR
Intervention: Lowest wear, moderate wear, highest wear toothbrushes
Number of subjects: 110
Study: 19606086

Group type: EXPERIMENTAL
Intervention: Active rTMS applied to the DLPFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15956071

Group type: EXPERIMENTAL
Intervention: Iron-gluconate 62.5 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Iron-gluconate 125 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (0 mg iron-gluconate)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Iron-gluconate (both doses)
Number of subjects: 14
Study: 11756982

Group type: EXPERIMENTAL
Intervention: HAART plus IL-2
Number of subjects: 9

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 9
Study: 10417454

Group type: EXPERIMENTAL
Intervention: Fentanyl-bupivacaine 0.1% mixture
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Fentanyl-bupivacaine 0.2% mixture
Number of subjects: 106

Group type: COMPARATOR
Intervention: Fentanyl alone
Number of subjects: 106
Study: 7576328

Group type: EXPERIMENTAL
Intervention: Improved STD treatment services
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Control group (standard STD treatment)
Number of subjects: 12000
Study: 2206015

Group type: EXPERIMENTAL
Intervention: GM1 treatment
Number of subjects: 0
Study: 6989464

Group type: EXPERIMENTAL
Intervention: Therapy with platelet antiaggregants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31431370

Group type: EXPERIMENTAL
Intervention: Hyperthermia (HT) combined with radiation treatment (RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging-guided focused ultrasound (MRgFUS)
Number of subjects: 0
Study: 30570289

Group type: EXPERIMENTAL
Intervention: Imagined contact
Number of subjects: 339
Study: 28566392

Group type: EXPERIMENTAL
Intervention: Delta ceramic total hip arthroplasty (THA)
Number of subjects: 252
Study: 26442158

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 70
Study: 23337364

Group type: EXPERIMENTAL
Intervention: Enhanced counseling (EC)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy (mDOT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 204
Study: 21324181

Group type: EXPERIMENTAL
Intervention: Sequential behaviour tailoring condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous behaviour tailoring condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18993042

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (IV NAC 150mg/kg on the first day followed by 50mg/kg/day for three days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 17535842

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study: 15581383

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg ODT
Number of subjects: 670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study: 11307043

Group type: EXPERIMENTAL
Intervention: 200 mg L‐Dopa
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9484419

Group type: EXPERIMENTAL
Intervention: Proton spectroscopy in subjects with idiopathic narcolepsy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Proton spectroscopy in normal subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Proton spectroscopy in subjects who slept during the scan
Number of subjects: 24
Study: 7699215

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVPI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorhexidine hydrochloride (Control)
Number of subjects: 30
Study: 2728828

Group type: EXPERIMENTAL
Intervention: 0.03 mg buprenorphine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.045 mg buprenorphine
Number of subjects: 45

Group type: COMPARATOR
Intervention: hyperbaric bupivacaine
Number of subjects: 45
Study: 5809554

Group type: EXPERIMENTAL
Intervention: High sucrose diet
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Normal diet after 14 days of high sucrose diet
Number of subjects: 19
Study: 30312895

Group type: EXPERIMENTAL
Intervention: Low home practice condition
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Medium home practice condition
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: High home practice condition
Number of subjects: 84

Group type: COMPARATOR
Intervention: Flexible home practice schedule
Number of subjects: 84
Study: 27313171

Group type: EXPERIMENTAL
Intervention: OSTRC Shoulder Injury Prevention Programme (exercise programme delivered 3 times per week for 7 months)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: OSTRC Shoulder Injury Prevention Programme
Number of subjects: 660
Study: 25542155

Group type: EXPERIMENTAL
Intervention: ABC priority driven approach to pelvic trauma management
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard pelvic trauma teaching without ABC concept
Number of subjects: 20
Study: 22952194

Group type: EXPERIMENTAL
Intervention: Grape consumption
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 40
Study: 20453069

Group type: EXPERIMENTAL
Intervention: Risk factors at admission for bleeding
Number of subjects: 15156

Group type: EXPERIMENTAL
Intervention: Active gastroduodenal ulcer
Number of subjects: 15156

Group type: EXPERIMENTAL
Intervention: Prior bleeding
Number of subjects: 15156

Group type: EXPERIMENTAL
Intervention: Low platelet count
Number of subjects: 15156

Group type: EXPERIMENTAL
Intervention: Other bleeding risk factors
Number of subjects: 15156
Study: 18505951

Group type: EXPERIMENTAL
Intervention: Jugular catheterization
Number of subjects: 750

Group type: COMPARATOR
Intervention: Femoral catheterization
Number of subjects: 750
Study: 16603855

Group type: EXPERIMENTAL
Intervention: 4% PRO 2000 gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5% PRO 2000 gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study: 12614254

Group type: EXPERIMENTAL
Intervention: Testim 100 mg/day
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Testim 50 mg/day
Number of subjects: 208

Group type: COMPARATOR
Intervention: Andropatch
Number of subjects: 208
Study: 10568572

Group type: EXPERIMENTAL
Intervention: Campath‐1H monoclonal antibody treatment (5-day pulse)
Number of subjects: 27
Study: 9005794

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg intravenously twice a day for 4 to 6 days, then orally for 4 to 6 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (broad spectrum antibiotics such as amplox, gentamicin, and 3rd generation cephalosporins)
Number of subjects: 35
Study: 1834115

Group type: EXPERIMENTAL
Intervention: Tetracosactrin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 97
Study: 6751888

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31473982

Group type: EXPERIMENTAL
Intervention: Family-centered empowerment program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 30745118

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with long-term androgen deprivation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy or next-generation hormone therapies
Number of subjects: 0
Study: 28757109

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily
Number of subjects: 22
Study: 25901540

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40